Last reviewed · How we verify
aspart insulin or lipro insulin
Aspart insulin is a rapid-acting insulin analog that binds to insulin receptors to promote glucose uptake and utilization in peripheral tissues.
Aspart insulin is a rapid-acting insulin analog that binds to insulin receptors to promote glucose uptake and utilization in peripheral tissues. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | aspart insulin or lipro insulin |
|---|---|
| Sponsor | Nanjing First Hospital, Nanjing Medical University |
| Drug class | Rapid-acting insulin analog |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Aspart insulin is a recombinant human insulin analog with a single amino acid substitution (aspartic acid at position B28) that allows faster absorption and onset of action compared to regular human insulin. It binds to the insulin receptor on muscle, fat, and liver cells to facilitate glucose transport into cells and promote anabolic metabolism, effectively lowering blood glucose levels in diabetic patients.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Injection site reactions
- Weight gain
- Lipodystrophy
Key clinical trials
- Comparison of Efficacy and Safety of Prandilin and NovoRapid in Newly Diagnosed Type 2 Diabetes (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: